(Q43036608)

12 November 2017

title

Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection (English)

1 reference

12 November 2017

1 reference

1 reference

Kuramoto IK

1

1 reference

12 November 2017

Moriya T

series ordinal

2

1 reference

12 November 2017

Schoening V

series ordinal

3

1 reference

12 November 2017

Holland PV

series ordinal

4

1 reference

12 November 2017

publication date

1 January 2002

1 reference

Journal of Viral Hepatitis

12 November 2017

published in

1 reference

12 November 2017

volume

9

1 reference

12 November 2017

issue

1

1 reference

12 November 2017

page(s)

36-42

1 reference

Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Development of a quantitative PCR assay for monitoring HCV viraemia levels in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Quantification of hepatitis C virus RNA in serum by branched DNA-based signal amplification assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

Serum HCV RNA titer does not predict the severity of liver damage in HCV carriers with normal aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00333.X

10.1046/J.1365-2893.2002.00333.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference